Health Trials

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

ConditionsCancer, MetastaticCancerCancer of PancreasCancer of LiverCancer of StomachCancer LiverCancer of RectumCancer of KidneyCancer of EsophagusCancer of CervixCancer of ColonCancer of LarynxCancer, LungCancer, BreastCancer, AdvancedCancer ProstateCancer of NeckCancer of SkinNeuroendocrine TumorsCarcinomaMismatch Repair DeficiencyBRCA Gene RearrangementNon Hodgkin LymphomaLeukemiaNon Small Cell Lung CancerCholangiocarcinomaGlioblastomaCentral Nervous System TumorMelanomaUrothelial CarcinomaBladder CancerOvarian CancerEndometrial CancerTesticular CancerBreast CancerCOVIDMyelofibrosisMyeloproliferative NeoplasmMyeloproliferative DisordersFollicular LymphomaMantle Cell LymphomaMarginal Zone LymphomaMyelodysplastic Syndromes
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorMassive Bio, Inc.

About this trial

International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinical impact on pts with advanced cancer to facilitate clinical trial enrollment (CTE), as well as the financial impact, and potential outcomes of the intervention.

Eligibility criteria

Qualifiers

Pts with solid and hematological malignancies;

Pts cancer-related biomarkers, gene variants, fusion and rearrangements (by immunohistochemistry, PCR, FISH or NGS): PD-L1, MSI (MMR), Claudin18.2, HER2/Neu, Tumor mutational burden/load (TMB), ABL1, ACVR1B, AKT1, AKT2, AKT3, ALK, APC, AR, ATM, ATRX, AURKA, AURKB, BAP1, BCL2, BCL6, BRAF, BRCA1, BRCA2, BTK, CCND1, CCND2, CCND3, CDK4, CDK6, CDKN1A/B, CEBPA, CHEK1, CHEK2, CSF1R, CTNNB1, DAXX, DDR1/2, DNMT3A, EGFR, ERBB2, ERBB3, ERBB4, ERCC4, ER, ESR1, FANCA, FAS, FBXW7, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, GATA3, GATA6, GNAS, HDAC1, HGF, HRAS, IDH1, IDH2, IGF1R, JAK1, JAK2, JAK3, KDR (VEGFR2), KIT, KRAS, MAP2K2 (MEK2), MAP3K1, MCL1, MDM2, MDM4, MEN1, MET, MSH2, MSH3, MSH6, MTOR, MUTYH, MYC, MYCL (MYCL1), NF1, NF2, NOTCH1, NPM1, NRAS, NTRK1, NTRK2, NTRK3, PALB2, PARP1, PARP2, PARP3, PBRM1, PDCD1 (PD1), PDCD1LG2 (PD-L2), PDGFRA, PDGFRB, PIK3C, PMS2, POLD1, POLE, PRDM1, PTCH1, PTEN, RAF1, RB1, RET, RICTOR, ROS1, RPTOR, SDHA/B/C, SMAD, SMARC, SMO, STK11, TGFBR2, TP53, TSC1, TSC2, VEGFA, VHL, WT1, ZNF217, ZNF703, CEACAM, NRG1, among others.

Decision to consider clinical trial pre-screening enrollment (CTE) by primary provider and/or patient

Disqualifiers

ECOG PS > 2;

Abnormal organ function;

Hospice enrollment

Trial design

Treatments tested in this trial

  • Clinical Trial Matching

Treatment groups

50,000 Participants
are divided into 1 treatment group

Sponsors and collaborators

Massive Bio, Inc.

Lead sponsor

Source ClinicalTrials.gov